Investor Resources

Innovative protein engineering technology, a broad portfolio of products, exceptional people, a reduced-risk strategy, and validating partnerships. These are the elements that position Xencor to be a leader in the development of protein-based drugs.

Since Xencor's founding in 1997, we have raised over $145 million from investors drawn to our remarkable scientific capabilities and the solid intellectual property we have built around them. With XmAb™2513 in a Phase I clinical trial in addition to a number of pre-clinical programs, we are at an exciting point in our growth as a biotechnology company.